Kunal Shah, an assistant professor of endocrinology at Rutgers University’s Robert Wood Johnson Medical School specializing in the treatment of obesity for more than a decade, sees reason for hope in newly approved diabetes medications hitting the market. Obesity rates have climbed steadily over the years: The Centers for Disease Control estimate about 42 percent of American adults are obese. Shah discusses Victoza (liraglutide) and Wegovy (semaglutide), two medications developed to treat Type 2 diabetes that recently have been approved to treat obesity. He also discusses a third diabetes drug, Mounjaro (tirzepatide), that has produced positive results in a trial against obesity. To read the full story.